Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Cancer Res

Retrieve available abstracts of 46 articles:
HTML format

Single Articles

    May 2024
  1. JOY JD, Malacrida B, Laforets F, Kotantaki P, et al
    Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity.
    Cancer Res. 2024 May 31. doi: 10.1158/0008-5472.CAN-23-3007.
    PubMed     Abstract available

    April 2024
  2. WATERS JA, Robinson M, Lujano-Olazaba O, Lucht C, et al
    Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2613.
    PubMed     Abstract available

    March 2024
  3. RAMANARAYANAN V, Oberdoerffer P
    AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy.
    Cancer Res. 2024;84:793-795.
    PubMed     Abstract available

    January 2024
  4. HUANG TT, Chiang CY, Nair JR, Wilson KM, et al
    AKT1 interacts with DHX9 to mitigate R-loop-induced replication stress in ovarian cancer.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-1908.
    PubMed     Abstract available

    December 2023
  5. HEO J, Kim YN, Shin S, Lee K, et al
    Serial circulating-tumor DNA analysis with a tumor naive next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429.
    PubMed     Abstract available

    October 2023
  6. BEDDOWS I, Fan H, Heinze K, Johnson BK, et al
    Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes.
    Cancer Res. 2023 Oct 24. doi: 10.1158/0008-5472.CAN-23-1362.
    PubMed     Abstract available

  7. ITO I, Yousef AMG, Chowdhury S, Dickson PN, et al
    Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
    Cancer Res. 2023;83:3184-3191.
    PubMed     Abstract available

    September 2023
  8. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    PubMed     Abstract available

    August 2023
  9. YU ZC, Li T, Tully E, Huang P, et al
    Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
    Cancer Res. 2023;83:2750-2762.
    PubMed     Abstract available

  10. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    PubMed     Abstract available

    July 2023
  11. WANG Y, Chen SY, Ta M, Senz J, et al
    Bi-allelic Dicer1 mutations in the gynecologic tract of mice drive lineage-specific development of DICER1 syndrome-associated cancer.
    Cancer Res. 2023 Jul 26:CAN-22-3620. doi: 10.1158/0008-5472.CAN-22-3620.
    PubMed     Abstract available

    June 2023
  12. LI QS, Zheng PS
    ESRRB inhibits the TGF-beta signaling pathway to drive cell proliferation in cervical cancer.
    Cancer Res. 2023 Jun 23:CAN-23-0067. doi: 10.1158/0008-5472.CAN-23-0067.
    PubMed     Abstract available

  13. ROSSI NM, Dai J, Xie Y, Wangsa D, et al
    Extrachromosomal Amplification of Human Papillomavirus Episomes Is a Mechanism of Cervical Carcinogenesis.
    Cancer Res. 2023;83:1768-1781.
    PubMed     Abstract available

    May 2023
  14. CAO K, Zhang G, Yang M, Wang Y, et al
    Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer.
    Cancer Res. 2023 May 12:CAN-22-3260. doi: 10.1158/0008-5472.CAN-22-3260.
    PubMed     Abstract available

  15. KELLIHER L, Lengyel E
    Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
    Cancer Res. 2023;83:1383-1385.
    PubMed     Abstract available

  16. PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
    BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
    Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
    PubMed     Abstract available

    April 2023
  17. LIU Y, Gusev A, Kraft P
    Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
    Cancer Res. 2023;83:1191-1202.
    PubMed     Abstract available

    February 2023
  18. ZHANG H, Jin X, Huang H
    Deregulation of SPOP in Cancer.
    Cancer Res. 2023;83:489-499.
    PubMed     Abstract available

  19. FERRI-BORGOGNO S, Zhu Y, Sheng J, Burks JK, et al
    Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.
    Cancer Res. 2023 Feb 14:CAN-22-1821. doi: 10.1158/0008-5472.CAN-22-1821.
    PubMed     Abstract available

    January 2023
  20. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    PubMed     Abstract available

    December 2022
  21. JUNGLES KM, Green MD
    Fat Fuels the Fire in Cervical Cancer.
    Cancer Res. 2022;82:4513-4514.
    PubMed     Abstract available

  22. HAWKINS SM, Nephew KP
    Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.
    Cancer Res. 2022;82:4511-4512.
    PubMed     Abstract available

  23. ALSINA-SANCHIS E, Mulfarth R, Moll I, Bohn S, et al
    Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages.
    Cancer Res. 2022;82:4414-4428.
    PubMed     Abstract available

    November 2022
  24. WANG CK, Chen TJ, Tan GYT, Chang FP, et al
    MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis.
    Cancer Res. 2022 Nov 10. pii: 710535. doi: 10.1158/0008-5472.CAN-22-1159.
    PubMed     Abstract available

    October 2022
  25. ATIYA HI, Frisbie L, Goldfeld E, Orellana T, et al
    Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation.
    Cancer Res. 2022 Oct 11. pii: 709712. doi: 10.1158/0008-5472.CAN-22-1294.
    PubMed     Abstract available

  26. MUHAMMAD N, Ruiz F, Stanley J, Rashmi R, et al
    Mono- and diunsaturated fatty acids sensitize cervical cancer to radiation therapy.
    Cancer Res. 2022 Oct 10. pii: 709678. doi: 10.1158/0008-5472.CAN-21-4369.
    PubMed     Abstract available

  27. CHAMBERS LM, Esakov Rhoades EL, Bharti R, Braley C, et al
    Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer.
    Cancer Res. 2022 Oct 7. pii: 709668. doi: 10.1158/0008-5472.CAN-22-0455.
    PubMed     Abstract available

  28. WANG Y, Huang P, Wang BG, Murdock T, et al
    Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis.
    Cancer Res. 2022 Oct 7. pii: 709669. doi: 10.1158/0008-5472.CAN-22-1620.
    PubMed     Abstract available

  29. HO GY, Kyran EL, Bedo J, Wakefield MJ, et al
    Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin.
    Cancer Res. 2022 Oct 7. pii: 709667. doi: 10.1158/0008-5472.CAN-21-4012.
    PubMed     Abstract available

  30. LU X, Xin DE, Du JK, Zou QC, et al
    Loss of LOXL2 promotes uterine hypertrophy and tumor progression by enhancing H3K36ac-dependent gene expression.
    Cancer Res. 2022 Oct 5. pii: 709611. doi: 10.1158/0008-5472.CAN-22-0848.
    PubMed     Abstract available

    September 2022
  31. ZHANG Y, Li J, Zhou Y, Li Z, et al
    And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
    Cancer Res. 2022;82:3249-3262.
    PubMed     Abstract available

    August 2022
  32. WANG Y, Xie H, Chang X, Hu W, et al
    Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer.
    Cancer Res. 2022 Aug 15. pii: 707741. doi: 10.1158/0008-5472.CAN-21-3819.
    PubMed     Abstract available

    July 2022
  33. CHENG L, Zhou S, Zhou S, Shi K, et al
    Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
    Cancer Res. 2022 Jul 20. pii: 707082. doi: 10.1158/0008-5472.CAN-22-0222.
    PubMed     Abstract available

    April 2022
  34. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    PubMed     Abstract available

    March 2022
  35. OSORIO JC, Zamarin D
    Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer.
    Cancer Res. 2022;82:766-768.
    PubMed     Abstract available

  36. ZHANG S, Yan C, Millar DG, Yang Q, et al
    Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Cancer Res. 2022;82:773-784.
    PubMed     Abstract available

    February 2022
  37. GHILARDI C, Moreira Barbosa C, Brunelli L, Ostano P, et al
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1223.
    PubMed     Abstract available

    December 2021
  38. MANDAL G, Biswas S, Anadon CM, Yu X, et al
    IgA-dominated humoral immune responses govern patients' outcome in endometrial cancer.
    Cancer Res. 2021 Dec 23. pii: 0008-5472.CAN-21-2376.
    PubMed     Abstract available

  39. O'CONNOR CM, Taylor SE, Miller KM, Hurst L, et al
    Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma.
    Cancer Res. 2021 Dec 17. pii: 0008-5472.CAN-21-1987.
    PubMed     Abstract available

    November 2021
  40. KANAKKANTHARA A, Hou X, Ekstrom TL, Zanfagnin V, et al
    Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-0732.
    PubMed     Abstract available

  41. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    PubMed     Abstract available

    October 2021
  42. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    PubMed     Abstract available

    September 2021
  43. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    PubMed     Abstract available

  44. HENKLE TR, Lam B, Kung YJ, Lin J, et al
    Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7-Expressing Carcinoma in the Cervicovaginal Tract.
    Cancer Res. 2021;81:4560-4569.
    PubMed     Abstract available

    June 2021
  45. CHEN L, Zhai Y, Wang Y, Fearon ER, et al
    Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Cancer Res. 2021;81:3309-3318.
    PubMed     Abstract available

    May 2021
  46. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.